EU AstraZeneca Ruling Raises Bar For IP Monopoly Abuse

Law360, New York (December 6, 2012, 9:41 PM EST) -- The European Union's highest court refused Thursday to overturn a €52.5 million ($68 million) abuse of dominance fine against AstraZeneca PLC, but it did raise the bar for the kinds of intellectual property defense tactics that could get a dominant market player into trouble with the bloc's antitrust agency.

The European Court of Justice upheld a 2010 ruling that largely endorsed the European Commission's decision to sanction the pharmaceutical giant for manipulating the drug and patent regulatory systems in order to block generic versions of ulcer...
To view the full article, register now.